<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">Minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) diagnostics is of high clinical relevance in patients with indolent B-cell Non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (B-NHL) and serves as a surrogate parameter to evaluate treatment effectiveness and long-term prognosis </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> diagnostics performed by real-time quantitative PCR (RQ-PCR) is the gold-standard and currently the most sensitive and the most broadly applied method in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) and mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>RQ-PCR analysis of the junctional regions of the rearranged immunoglobulin heavy-chain gene (IgH) serves as the most broadly applicable <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> target in B-NHL (∼80%) </plain></SENT>
<SENT sid="3" pm="."><plain>Chromosomal translocations as t(14;18) translocation in FL and t(11;14) translocation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> can be used in selected <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtypes </plain></SENT>
<SENT sid="4" pm="."><plain>In patients with B-cell <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, both flow-cytometry as well as RQ-PCR are equally suitable for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> assessment as long as a sensitivity of ≤10(-4) shall be achieved.<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> diagnostics targeting the IgH gene is complex and requires extensive knowledge and experience because the junctional regions of each <z:hpo ids='HP_0002665'>lymphoma</z:hpo> have to be identified before the patient-specific RQ-PCR assays can be designed for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> monitoring </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> of the IgH region occurring during B-cell development of germinal center and post-germinal center <z:hpo ids='HP_0002665'>lymphomas</z:hpo> may hamper appropriate primer binding leading to false negative results </plain></SENT>
<SENT sid="6" pm="."><plain>The translocations mentioned above have the advantage that consensus forward primers and probes, both placed in the breakpoint regions of chromosome 18 in FL and chromosome 11 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, can be used in combination with a reverse primer placed in the IgH joining region of chromosome 14 </plain></SENT>
<SENT sid="7" pm="."><plain>RQ-PCR-based methods can reach a good sensitivity (≤10(-4)) </plain></SENT>
<SENT sid="8" pm="."><plain>This chapter provides <z:hpo ids='HP_0000001'>all</z:hpo> relevant background information and technical aspects for the complete laboratory process from detection of the clonal IgH gene rearrangement and the chromosomal translocations at diagnosis to the actual <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> measurements in clinical follow-up samples of B-NHL </plain></SENT>
<SENT sid="9" pm="."><plain>However, it should be noted that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> diagnostics for clinical treatment protocols has to be accompanied by regular international quality control rounds to ensure the reproducibility and reliability of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> results </plain></SENT>
</text></document>